CD22 Inhibitors
CD22 inhibitors are a class of chemical compounds designed to target and modulate the activity of the CD22 protein, which plays a crucial role in immune regulation and B-cell function. CD22, also known as Siglec-2 (Sialic acid-binding Ig-like lectin 2), is a transmembrane glycoprotein primarily expressed on the surface of B cells, including both mature B cells and B-cell precursors. It functions as a negative regulator of B-cell receptor (BCR) signaling, helping to curb excessive activation of B cells and maintaining immune tolerance. CD22 inhibitors are designed to interfere with CD22's interaction with sialic acid residues on glycoproteins, a critical step in its immunomodulatory function.
The mechanism of action of CD22 inhibitors typically involves binding to the CD22 protein, blocking its engagement with sialic acid residues. This disruption of CD22's binding ability can lead to enhanced BCR signaling, thereby promoting B-cell activation. CD22 inhibitors may also trigger antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), leading to the elimination of CD22-expressing B cells. These compounds are of interest in the field of immunology and oncology, as they have the ability to modulate immune responses.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chlorambucil | 305-03-3 | sc-204682 sc-204682A | 250 mg 1 g | $51.00 $120.00 | 3 | |
Chlorambucil may alkylate DNA, leading to the disruption of cellular processes and potentially decreasing CD22 expression. | ||||||
Methylprednisolone | 83-43-2 | sc-205749 sc-205749A | 100 mg 500 mg | $115.00 $260.00 | 1 | |
Methylprednisolone can affect transcription factors that may downregulate CD22 expression as part of its anti-inflammatory action. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $76.00 $143.00 $469.00 $775.00 | 18 | |
Cyclophosphamide, a cytotoxic agent, could inhibit the proliferation of B-cells, potentially reducing CD22 expression. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin might modulate signal transduction pathways, possibly influencing the expression of proteins like CD22. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A can inhibit calcineurin, which may result in altered transcription and decreased CD22 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a pathway that could regulate the expression of proteins such as CD22. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $36.00 $107.00 | 1 | |
Mycophenolate mofetil impedes purine synthesis, potentially affecting B-cell function and CD22 expression. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Hydroxychloroquine can affect endosomal pH, which might influence signal transduction and CD22 expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib causes proteasome inhibition, which could lead to altered protein turnover and reduced CD22 surface expression. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib targets Bruton's tyrosine kinase, possibly impacting signaling pathways that control CD22 expression. | ||||||